Compare SNT & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNT | GRML |
|---|---|---|
| Founded | 1965 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 29.2M |
| IPO Year | 2023 | 2022 |
| Metric | SNT | GRML |
|---|---|---|
| Price | $1.43 | $6.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.9K | ★ 18.0M |
| Earning Date | 11-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.16 |
| 52 Week High | $5.34 | $18.21 |
| Indicator | SNT | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 31.12 | 49.14 |
| Support Level | N/A | $0.28 |
| Resistance Level | $1.67 | $11.66 |
| Average True Range (ATR) | 0.08 | 1.55 |
| MACD | -0.01 | -0.66 |
| Stochastic Oscillator | 0.00 | 12.21 |
Senstar Technologies Corp is an international provider of comprehensive physical, video, and access control security products and solutions. The company offers comprehensive solutions for critical sites, which leverage its broad portfolio of homegrown PIDS (Perimeter Intrusion Detection Systems), advanced VMS and SMS (Video Management Software and Security Management Software) with native IVA (Intelligent Video Analytics) security solutions, as well as access control products and technologies. Geographically, the company operates in North America, which derives maximum revenue; Europe; APAC; South and Latin America; and Others.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.